Labelling Review row-Online

Primary Antibodies
PETA-3 (CD151)
Clone RLM30
1 mL lyophilized NCL-CD151 P (HIER)
See also CD151 (PETA-3) on page 87.
P-glycoprotein (CD243)
Clone 5B12
1 mL lyophilized NCL-PGLYm F P (HIER)
The resistance of tumor cells to cytotoxic chemotherapeutic drugs is a
major problem in the treatment of cancer. Studies have linked the presence
of a 170 to 180 kD cell membrane protein, P-glycoprotein, with resistance to
a wide range of lipophilic chemotherapeutic drugs, a phenomenon known as
multidrug resistance. P-glycoprotein is reported to be expressed in transporting
epithelia of several normal tissues, including liver, kidney, colon,
adrenal and brain.
Placental Alkaline Phosphatase
Clone 8A9
1 mL, 0.1 mL lyophilized NCL-PLAP-8A9 F P (HIER)
1 mL liquid NCL-L-PLAP-8A9 F P (HIER)
7 mL ready-to-use RTU-PLAP-8A9 F P (HIER)
7 mL Bond ready-to-use PA0161 P (HIER)
Placental alkaline phosphatase (PLAP) is a membrane-associated
sialoglycoprotein enzyme normally present at high concentration in syncytiotrophoblasts
within the placenta during the third trimester of gestation.
The expression of PLAP was originally thought to be restricted to term
placenta but a human PLAP-like variant has been described which shares
more than 85 percent homology with PLAP itself. This high degree of
homology between PLAP and PLAP-like enzyme together with crossreacting
antibodies has led to some confusion of the distribution of PLAP
and PLAP-like enzyme in various tissues. PLAP is reported to be expressed
only in normal term placenta, endocervix and fallopian tube and also in
ovarian and proximal gastrointestinal tumors. PLAP expression is rare in
malignant germ cell tumors. PLAP-like enzyme is reported to be
predominantly found in normal fetal and neonatal testis, and in thymus. It is
also commonly expressed in germ cell tumors and more recently described
in seminomas.
Product Specific Information
Reports indicate that clone 8A9 stains seminomas and placenta indicating a
specificity for both PLAP and PLAP-like enzyme.
Refer to page 39 for the Bond ready-to-use format.
Human seminoma: immunohistochemical staining for placental alkaline phosphatase using
NCL-PLAP-8A9. Note intense membrane staining of tumor cells. Paraffin section.
/ 150
For detailed information on all products please visit our website:
www.leica-microsystems.com
Plasma Cell Marker
Clone LIV3G11
1 mL lyophilized NCL-PC P (Enzyme)
The plasma cell is the resultant terminal stage of B cell differentiation and
apart from morphological features may be distinguished from other B cells
by their lack of surface HLA class I and class II antigens, surface
immunoglobulin, Fc and C3 receptors or presence of intracytoplasmic
immunoglobulin. There have been some interesting studies where non-
Hodgkin’s lymphomas have been differentiated from plasmacytomas and
myelomas based on plasma cell markers (Seegmiller et al., American
Journal of Clinical Pathology. 127(2):172-174 (2007)).
Human tonsil: immunohistochemical staining for plasma cells using NCL-PC. Note cytoplasmic
staining of plasma cells. Paraffin section.
Plasminogen Activator Inhibitor (Type 1)
Clone TJA6
1 mL, 0.1 mL lyophilized NCL-PAI-1 P
Plasminogen activator inhibitor (Type 1, PAI-1) is a 48 kD protein which
inhibits the conversion of plasminogen to plasmin. It is the principal inhibitor
of the plasminogen activators t-PA and u-PA. PAI-1 is structurally related to
the serine protease inhibitor (serpin) superfamily. The serpins are known to
undergo a conformational rearrangement upon cleavage of the reactive
central peptide bond (P 1-P 1') and it is this conformational difference
between the active and cleaved forms which determine their reactivity. The
PAI-1 protein is reported to be overexpressed in a number of malignancies
including ovarian cancers and derived cell lines, endometrial cancers,
cervical cancer, malignant brain cancers, nasopharyngeal carcinomas,
breast tumors, head and neck squamous cell carcinomas and gastric
cancers. PAI-1 is also reported to be expressed by endothelial cells and is
stored in platelets.
Human ovarian adenocarcinoma: immunohistochemical staining for plasminogen activator
inhibitor type 1 using NCL-PAI-1. Note intense cytoplasmic staining of malignant tumor cells.
Paraffin section.
Products in this catalog are subject to regulatory approval.
This catalog is not for use in the USA.